eGFR vs Creatinine Clearance: Key Differences for CKD and Medication Dosing

Quick Answer: Use eGFR (estimated glomerular filtration rate) for diagnosing and staging chronic kidney disease (CKD). For medication doses, the 2024 KDIGO guideline says "validated eGFR equations using SCr are appropriate for drug dosing" for most people, and the FDA's March 2024 guidance recommends eGFR over Cockcroft-Gault creatinine clearance (CrCl) for new pharmacokinetic studies. Many older drug labels still give dose adjustments by CrCl, so near a label's cut-off, use the measure that label names. The units differ: eGFR is normalized to body surface area (mL/min/1.73m²), CrCl is in mL/min, and for dosing both bodies call for eGFR converted to mL/min.

---

Understanding Kidney Function Measurement

Your kidneys filter waste products from your blood, and measuring how efficiently they do this helps doctors detect kidney disease and adjust medication doses. The glomerular filtration rate (GFR) is the volume of fluid filtered through the kidneys' glomeruli per minute—essentially, how well your kidneys are working.

Since directly measuring GFR requires complex procedures (injecting contrast agents and collecting timed urine samples), we use estimated values based on blood tests:

• eGFR (estimated GFR) - Calculated from serum creatinine, age, and sex (current equations leave race out; KDIGO 2024: "Use of race in the computation of eGFR should be avoided")
• CrCl (creatinine clearance) - Calculated from serum creatinine, age, sex, and body weight

Both estimate kidney function, but they use different formulas, report results differently, and serve different clinical purposes. Understanding when to use each is critical for both kidney disease management and safe medication use.

---

Side-by-Side Comparison

---

eGFR (Estimated Glomerular Filtration Rate): For CKD Staging

How eGFR Works

eGFR is calculated using equations that estimate how much blood the kidneys filter per minute, normalized to a standard body surface area of 1.73 m². The most current equation is:

CKD-EPI 2021 (race-free equation): Uses serum creatinine, age, and sex. This replaced the 2009 CKD-EPI equation that included race, which was found to perpetuate health disparities.

Older equations (now outdated):

• MDRD (Modification of Diet in Renal Disease) - Less accurate than CKD-EPI
• CKD-EPI 2009 - Included race coefficient (no longer recommended)

Your lab report automatically calculates and reports eGFR whenever serum creatinine is measured. Normal eGFR is ≥90 mL/min/1.73m². An eGFR below 60 that lasts at least 3 months meets the KDIGO definition of chronic kidney disease ("abnormalities of kidney structure or function, present for a minimum of 3 months").

CKD Staging Using eGFR

eGFR is the foundation of the KDIGO (Kidney Disease: Improving Global Outcomes) CKD classification:

• G1 (≥90): Normal or high kidney function (CKD only if kidney damage is present)
• G2 (60-89): Mild reduction (CKD if kidney damage present)
• G3a (45-59): Mild-moderate reduction
• G3b (30-44): Moderate-severe reduction
• G4 (15-29): Severe reduction
• G5 (<15): Kidney failure. KDIGO says to start dialysis "based on a composite assessment of a person's symptoms, signs, QoL, preferences, level of GFR, and laboratory abnormalities," not on the number alone.

These stages guide referral, planning, and monitoring. KDIGO 2024 lists an eGFR below 30, or a 5-year risk of kidney failure above 3-5%, among the reasons to refer to kidney specialists.

Advantages of eGFR

1. Standardized for CKD diagnosis: The 2024 KDIGO guideline recommends "using a validated GFR estimating equation" for CKD classification and staging, the same equation within a region, and no race term. This page uses the race-free CKD-EPI 2021 equation.

2. Automatically reported by labs: Every time your doctor orders a basic metabolic panel (BMP) or comprehensive metabolic panel (CMP), eGFR is calculated and reported automatically. No additional work is needed.

3. Normalized to body size: The normalization to 1.73 m² body surface area allows fair comparison between a 5-foot-tall person and a 6-foot-tall person. This removes body size as a confounding variable when assessing kidney disease severity.

4. No race term: The CKD-EPI 2021 equation estimates GFR from creatinine, age, and sex only, without the race coefficient of older equations.

5. Tracks disease progression: Serial eGFR measurements over time show whether kidney function is stable, improving, or declining. KDIGO 2024: "a change in eGFR of >20% on a subsequent test exceeds the expected variability and warrants evaluation."

6. Can be converted for dosing: For people with extremes of body weight, KDIGO 2024 says "eGFR nonindexed for body surface area (BSA) may be indicated" for dosing, and that equations combining creatinine and cystatin C, or measured GFR, may be needed where more accuracy is required.

Limitations of eGFR

1. Labels may name a different measure: Many older drug labels give dose adjustments by CrCl (Cockcroft-Gault). KDIGO 2024 acknowledges "inconsistency between this guidance and those found in the package inserts." Near a label's cut-off, the two measures can put a patient on different sides of it.

2. Normalized units can be confusing for dosing: The normalization to 1.73 m² means eGFR doesn't represent actual kidney clearance in a specific patient. For a 45 kg elderly woman, her actual GFR is lower than the reported eGFR suggests, which matters for drug elimination.

3. Requires "de-indexing" for actual clearance: Research indicates that drug elimination correlates better with non-indexed (de-normalized) eGFR than the standard indexed eGFR. This requires additional calculation: multiply eGFR by (patient's BSA / 1.73 m²). The FDA's March 2024 guidance asks for exactly this when a dose is given by eGFR: "use the eGFR expressed as mL/minute rather than the eGFR referenced to a BSA value of 1.73 m2."

4. Less accurate in acute kidney injury: eGFR equations assume stable kidney function. In AKI, creatinine is changing rapidly, and eGFR significantly underestimates or overestimates true GFR. Direct measurement or clinical judgment is needed.

5. Affected by non-kidney factors: Muscle mass significantly affects creatinine production. Bodybuilders or athletes may have lower eGFR despite normal kidneys (high creatinine from muscle). Conversely, elderly or malnourished patients may have falsely high eGFR (low creatinine from low muscle mass).

---

Creatinine Clearance (CrCl): The Measure Many Drug Labels Use

How CrCl Works

Creatinine clearance estimates how much blood the kidneys clear of creatinine per minute, reported in mL/min (not normalized). The standard equation is:

Cockcroft-Gault formula (1976):

• Men: CrCl = [(140 − age) × weight] / (72 × serum creatinine)
• Women: CrCl = [(140 − age) × weight × 0.85] / (72 × serum creatinine)

Where weight is in kg, age in years, creatinine in mg/dL.

This formula uses body weight as a key variable. In overweight or obese patients, the FDA's 2024 guidance notes that ideal or adjusted body weight "is likely to provide a more accurate estimate of renal function than using actual body weight."

Drug Dosing with CrCl

There is no general rule for how much to reduce a dose. Each drug's label sets its own kidney-function cut-offs and its own adjustments, and some name eGFR instead of CrCl. Use the table in that drug's label, and ask a pharmacist when a patient is near a cut-off.

Common drug classes requiring renal dose adjustment:

• Antibiotics: Aminoglycosides, vancomycin, fluoroquinolones, beta-lactams
• Anticoagulants: Enoxaparin, dabigatran, rivaroxaban, apixaban
• Antiviral: Acyclovir, ganciclovir, tenofovir
• Chemotherapy: Carboplatin (dosed by AUC from GFR with the Calvert formula), cisplatin, methotrexate
• Diabetes medications: Metformin, SGLT2 inhibitors
• Other: Digoxin, gabapentin, lithium

Advantages of CrCl

1. Matches many older labels: Many drug labels written before the newer eGFR equations give their dose adjustments by Cockcroft-Gault CrCl. When a label names CrCl, using CrCl follows the data the label was built on. (For new drugs, the FDA's March 2024 guidance recommends eGFR: "use of eGFR to determine renal function in PK studies is recommended over eCLcr.")

2. Already in mL/min: CrCl is expressed for the individual patient, not normalized to a standard body size, which is the unit drug clearance depends on. eGFR can be converted to mL/min too (see below).

3. Incorporates body weight: The formula includes weight directly, which also makes the result depend on which weight is used.

4. Long track record: Cockcroft-Gault has been used for drug dosing since 1976, and many existing dosing references were built with it.

5. Familiar in practice: Many pharmacy protocols and decision-support tools are set up around CrCl thresholds.

Limitations of CrCl

1. Overestimates true GFR: Creatinine is not only filtered by the glomeruli but also secreted by the renal tubules, so creatinine clearance runs higher than true GFR. That is one reason it is not used for CKD staging. A kidney-function estimate that reads too high can lead to a dose that is too high.

2. Not automatically reported: Unlike eGFR, labs don't calculate and report CrCl. Clinicians must manually calculate it or use online calculators, which adds a step and increases risk of error. Use our Creatinine Clearance Calculator for easy calculation.

3. Requires body weight: You need an accurate, recent weight measurement. If weight isn't available or is inaccurate (common in hospitalized patients with fluid overload or edema), CrCl will be incorrect.

4. Less accurate in obesity: The standard formula uses actual body weight, which overestimates CrCl in obese patients (fat doesn't contribute to creatinine clearance). Adjusted body weight should be used: ABW = IBW + 0.4 × (actual weight − IBW), but this is often forgotten.

5. Low muscle mass: Frail or very elderly patients produce less creatinine, which can make any creatinine-based estimate, CrCl or eGFR, read higher than true kidney function.

6. Old formula: Cockcroft-Gault dates to 1976 and was developed in a limited population. KDIGO 2024 notes its "lack of validation and its relative inaccuracy compared with other validated eGFR equations," yet many dosing references still use it.

---

When to Use eGFR vs CrCl

Use eGFR (CKD-EPI 2021) If:

✓ Diagnosing or staging chronic kidney disease: A validated eGFR equation is what the KDIGO 2024 guideline recommends for CKD classification (stages G1-G5). Use eGFR to determine if a patient has CKD and how severe it is.

✓ Monitoring CKD progression over time: Serial eGFR measurements track whether kidney function is stable, declining, or improving. KDIGO 2024 treats a change of more than 20% between tests as worth evaluating, and lists an eGFR below 30 among the reasons to refer to kidney specialists.

✓ Assessing cardiovascular risk: Lower eGFR is linked to higher cardiovascular risk.

✓ You don't have an accurate weight: If body weight is unknown, unreliable (fluid overload, anasarca), or unavailable, eGFR can still be calculated using creatinine, age, and sex alone.

✓ Extreme body sizes, with care: In very large or very small patients, neither creatinine-based estimate is reliable. For dosing, KDIGO 2024 suggests eGFR not indexed to body surface area, and equations that combine creatinine and cystatin C, or measured GFR, where more accuracy is needed.

✓ Comparing across patients or populations: For research, quality metrics, or population health, eGFR's standardization allows fair comparison regardless of body size.

Use CrCl (Cockcroft-Gault) If:

✓ The drug's label names CrCl: If the package insert gives dose adjustments by CrCl, calculate CrCl. Near the label's cut-off, eGFR and CrCl can fall on different sides of it.

✓ High-risk medications: For drugs with narrow therapeutic windows (aminoglycosides, vancomycin, digoxin, lithium), follow the drug's label and your pharmacy's monitoring protocol. KDIGO 2024 says equations combining creatinine and cystatin C, or measured GFR, "may be indicated" where more accuracy is required.

✓ Following institutional protocols: Many hospitals and pharmacy protocols specify CrCl for drug dosing decisions. Use CrCl for consistency with local standards and computerized alerts.

✓ Carboplatin dosing: Carboplatin is dosed by AUC (area under the curve) with the Calvert formula, which takes a GFR value. KDIGO 2024 says measured GFR "may be the preferred method to guide the initial dosing" of carboplatin and some other anticancer drugs; in practice centres also use Cockcroft-Gault CrCl or eGFR. Follow your oncology protocol.

✓ You have an accurate weight: If body weight is reliable and recent, CrCl can be calculated accurately. For outpatients or stable patients, this is usually straightforward.

---

The Shift: eGFR for Drug Dosing

The 2024 guidance has moved toward eGFR for dosing:

• KDIGO 2024: "For most people and clinical settings, validated eGFR equations using SCr are appropriate for drug dosing." It also acknowledges "inconsistency between this guidance and those found in the package inserts."
• FDA (March 2024): "Because of the widespread availability and incorporation of eGFR into current clinical practice, use of eGFR to determine renal function in PK studies is recommended over eCLcr." It still considers "any contemporary, widely accepted, and clinically applicable estimating equation" reasonable for those studies. The guidance is addressed to drug makers designing studies, not to prescribers.
• Units: both call for eGFR in mL/min when dosing: the FDA says "use the eGFR expressed as mL/minute rather than the eGFR referenced to a BSA value of 1.73 m2." That conversion needs the patient's height and weight.

What has not changed: many existing labels still give their adjustments by Cockcroft-Gault CrCl, and many hospital protocols are built around CrCl. For a patient near a label's cut-off, use the measure that label names and check with pharmacy.

---

Practical Approach: Use Both for Their Intended Purposes

Recommended workflow:

For CKD management:

1. Use eGFR (CKD-EPI 2021) from the lab report
2. Stage CKD (G1-G5) based on eGFR
3. Track eGFR trends over time (annual or more frequent in advanced CKD)
4. Refer to kidney specialists per KDIGO 2024 (for example, eGFR below 30, a 5-year kidney failure risk above 3-5%, or a sustained drop of more than 20%)

For medication dosing:

1. Check the drug package insert or dosing guideline
2. If it specifies CrCl, calculate CrCl using Cockcroft-Gault (use our CrCl Calculator)
3. If it specifies eGFR in mL/min/1.73m², use the lab-reported value; if it specifies eGFR in mL/min, convert the lab value with the patient's body surface area first
4. If dose is near a cutoff threshold, consider calculating both and discussing with pharmacy
5. For overweight or obese patients, ideal or adjusted body weight in the CrCl formula is likely more accurate than actual weight (FDA 2024); a common adjusted weight is ABW = IBW + 0.4 × (actual − IBW)

When in doubt:

• Near a dosing cutoff? Use the measure the package insert names
• No weight available? eGFR from the lab can still stage kidney function
• Very large, very small, or frail patient? Creatinine-based estimates are less reliable; ask pharmacy, and consider cystatin C
• High-risk medication? Consult pharmacy

---

Worked Examples: How Far Apart the Two Can Be

These examples show the arithmetic only: eGFR from the CKD-EPI 2021 creatinine equation, CrCl from Cockcroft-Gault with actual body weight. They are not dosing advice. For any drug, the label decides which measure and which cut-offs apply.

Example 1: 72-year-old woman, 55 kg, creatinine 1.3 mg/dL → eGFR ≈ 44 mL/min/1.73m² (G3b). CrCl ≈ 34 mL/min. A label cut-off between 34 and 44 would place her on different sides depending on the measure used.

Example 2: 45-year-old man, 180 kg, creatinine 1.0 mg/dL → eGFR ≈ 95 mL/min/1.73m² (G1). CrCl with actual weight ≈ 238 mL/min. Actual weight in a very heavy patient makes CrCl implausibly high; this is why ideal or adjusted weight is used in obesity.

Example 3: 68-year-old woman, 62 kg, creatinine 1.8 mg/dL → eGFR ≈ 30 mL/min/1.73m² (on the G3b/G4 border). CrCl ≈ 29 mL/min. Both sit right at a common cut-off of 30, where the drug's label and a pharmacist should decide.

Example 4: 80-year-old man, 58 kg, creatinine 0.9 mg/dL → eGFR ≈ 86 mL/min/1.73m² (G2). CrCl ≈ 54 mL/min. In older, lighter patients Cockcroft-Gault often gives a much lower number than eGFR, so the choice of measure matters for any drug with a cut-off in that range.

---

Key Takeaways

• eGFR (CKD-EPI 2021) is the standard for CKD diagnosis and staging—use it to determine if a patient has kidney disease and how severe it is.

• For drug dosing, KDIGO 2024 says validated eGFR equations are appropriate for most people, and the FDA's March 2024 guidance recommends eGFR over Cockcroft-Gault CrCl for new studies. Many older labels still use CrCl.

• Units differ: eGFR is normalized (mL/min/1.73m²), CrCl is in mL/min. For dosing, both KDIGO and the FDA point to eGFR converted to mL/min with the patient's body surface area.

• The two can differ a lot in obesity, older age, low muscle mass, and extreme body sizes. See the worked examples above.

• Always check the drug package insert to see whether it references eGFR or CrCl, and use the measure it names, especially near a cut-off.

---

Frequently Asked Questions

Why does my eGFR say 90 but my CrCl is 65?

This is common, especially in elderly or small-statured patients. eGFR is normalized to a standard body surface area of 1.73 m². If you're smaller than this (e.g., elderly woman, 5'2", 110 lbs), your actual kidney clearance is lower than the normalized eGFR suggests. CrCl uses your actual weight and reflects your true clearance—65 mL/min in your case. For medication dosing, use the CrCl value (65 mL/min) if the drug label references CrCl. For CKD staging, use eGFR (90 mL/min/1.73m²), which indicates no significant kidney disease.

Should I use ideal body weight or actual body weight for CrCl in obese patients?

The FDA's 2024 guidance says that in overweight or obese patients, ideal or adjusted body weight "is likely to provide a more accurate estimate of renal function than using actual body weight." A common adjusted weight is ABW = IBW + 0.4 × (actual weight − ideal weight). Using actual weight overestimates CrCl because adipose tissue adds little creatinine. Which weight to use, and from what body size, is set by the drug's label or your pharmacy's protocol.

My eGFR is 50 but creatinine is only 1.2—how can kidney function be that low?

Creatinine alone doesn't tell you kidney function—it must be interpreted in context of age, sex, and muscle mass. A creatinine of 1.2 mg/dL means very different things for different people: For a 25-year-old man, 1.2 gives an eGFR of about 86 (near normal). For a 75-year-old woman, 1.2 gives an eGFR of about 47 (G3a). This is why we calculate eGFR or CrCl rather than using creatinine alone.

Can I use eGFR for antibiotic dosing?

It depends on the specific antibiotic, its label, and your institution's protocol. KDIGO 2024 considers validated eGFR equations appropriate for dosing in most people, but many antibiotic labels give their adjustments by CrCl. For aminoglycosides and vancomycin, which have narrow therapeutic windows, follow your pharmacy's dosing and drug-level monitoring protocol.

Which is more accurate, eGFR or CrCl?

For estimating true glomerular filtration rate, validated eGFR equations such as CKD-EPI 2021 are more accurate; KDIGO 2024 notes Cockcroft-Gault's "relative inaccuracy compared with other validated eGFR equations." Creatinine clearance also runs above true GFR because the tubules secrete some creatinine. For drug dosing, what matters is which measure the drug's label was built on, and for eGFR, converting it to mL/min. Where more accuracy is needed, KDIGO suggests adding cystatin C or measuring GFR directly.

Do I need to de-index eGFR for drug dosing?

Some experts recommend de-indexing (denormalizing) eGFR for drug dosing, especially in patients whose body size differs significantly from the reference 1.73 m² BSA. Formula: De-indexed eGFR = eGFR × (patient's BSA / 1.73 m²). Calculate BSA using the DuBois formula: BSA (m²) = 0.007184 × height (cm)^0.725 × weight (kg)^0.425. The FDA's March 2024 guidance asks for this when a dose is set by eGFR ("use the eGFR expressed as mL/minute"), and KDIGO 2024 says non-indexed eGFR "may be indicated" in people with extremes of body weight.

What if eGFR and CrCl give different dose recommendations?

This happens when a patient is near a dosing cutoff threshold. Example: eGFR = 32 mL/min/1.73m², CrCl = 28 mL/min, drug cutoff is 30 mL/min. What do you do? (1) Check the package insert and use the measure it specifies. (2) Consider the whole patient: frailty, recent illness, changing kidney function, other organ problems. (3) Ask pharmacy or nephrology, especially for high-risk medications. In this example, if the label says CrCl, the CrCl of 28 is the number the label's table applies to.

Should children use eGFR or CrCl?

Children use pediatric equations, which include height (the bedside Schwartz equation is one). Pediatric eGFR is reported as mL/min/1.73m² (like adults) and is used for CKD staging in children. For medicines, children are usually dosed by weight; KDIGO 2024 adds that "in addition to the usual weight-based dosing for children," specific dosing guidance should be followed for neonates, whose GFR is lower. Consult pediatric nephrology or pharmacy for any child with reduced kidney function.

---

Related Tools and Resources

• eGFR Calculator - Calculate estimated glomerular filtration rate using CKD-EPI 2021
• Creatinine Clearance Calculator - Calculate CrCl using Cockcroft-Gault formula
• BUN/Creatinine Ratio - Assess kidney function and hydration status
• Kidney Function Guide - Comprehensive resource on CKD staging and management
• Ideal Weight Calculator - Calculate ideal body weight for adjusted body weight in CrCl
• Body Surface Area Calculator - Calculate BSA for de-indexing eGFR

---

Sources

• KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease | Kidney International
• Pharmacokinetics in Patients with Impaired Renal Function: Study Design, Data Analysis, and Impact on Dosing (March 2024) | FDA
• Estimating Glomerular Filtration Rate: Adults (CKD-EPI 2021 equation) | NIDDK
• Estimating Renal Function for Drug Dosing Decisions | NCBI PMC
• Determining Drug Dosing in Adults with Chronic Kidney Disease | NIDDK
• Calculating kidney function | NHS Specialist Pharmacy Service

---

Disclaimer: This information is for educational purposes only and does not constitute medical advice. Medication dosing decisions should be made by qualified healthcare providers using the most current drug labeling information, patient-specific factors, and clinical judgment. Always verify dose adjustments with a pharmacist or prescribing information before administering renally cleared medications.